{
	"symbol": "BCT",
	"name": "BriaCell Therapeutics Corp.",
	"price": 1.01,
	"priceChange": -0.08,
	"percentChange": -7.339449,
	"exchangeName": "Toronto Stock Exchange",
	"exShortName": "TSX",
	"exchangeCode": "TSX",
	"marketPlace": null,
	"sector": "Healthcare",
	"industry": "Biotechnology",
	"volume": 102306,
	"openPrice": 1.1,
	"dayHigh": 1.1,
	"dayLow": 0.96,
	"MarketCap": 36544993,
	"MarketCapAllClasses": 36196543,
	"peRatio": "",
	"prevClose": 1.09,
	"dividendFrequency": null,
	"dividendYield": null,
	"dividendAmount": null,
	"dividendCurrency": null,
	"beta": 1.814605,
	"eps": null,
	"exDividendDate": "",
	"longDescription": "BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.",
	"fulldescription": "BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.",
	"website": "http://www.briacell.com",
	"email": "",
	"phoneNumber": "+1 604 921-1810",
	"fullAddress": "235 - 15th Street,Suite 300, West Vancouver, Vancouver, BC, CA",
	"employees": "11",
	"shareOutStanding": 36183161,
	"totalDebtToEquity": "",
	"totalSharesOutStanding": 35838161,
	"sharesESCROW": 0,
	"vwap": 1.00450884,
	"dividendPayDate": null,
	"weeks52high": 8,
	"weeks52low": 0.64,
	"alpha": -0.019781,
	"averageVolume10D": 39648,
	"averageVolume20D": 28381,
	"averageVolume30D": 33180,
	"averageVolume50D": 63668,
	"priceToBook": -11.24,
	"priceToCashFlow": -0.6,
	"returnOnEquity": "",
	"returnOnAssets": 57.98,
	"day21MovingAvg": 0.987619,
	"day50MovingAvg": 1.065,
	"day200MovingAvg": 2.09495,
	"dividend3Years": "",
	"dividend5Years": "",
	"datatype": "equity",
	"issueType": "CS",
	"close": 1.01,
	"qmdescription": "Biotechnology",
	"__typename": "Company"
}